Are Cannabis, Cannabis-Derived Products, and Synthetic Cannabinoids a Therapeutic Tool for Rheumatoid Arthritis? A Friendly Summary of the Body of Evidence

Clara Schulze-Schiappacasse, MD,* Josefina Durán, MD, MSc,‡‡ Rocio Bravo-Jeria, B.Sc.P.S,§
Francisca Verduge-Paiva, DDS, MSc,§§
Macarena Morel, Librarian, Dip. Evidence-Based Medicine,§ and Gabriel Rada, MD†§§

Background: Symptom management in rheumatoid arthritis (RA) remains a complex challenge. Widespread use of cannabis-based medicines for a myriad of symptoms has fostered rheumatologists’ interest. However, their safety and efficacy in RA remain unclear.

Objective: The aim of this study was to perform a structured summary of the body of evidence in order to determine whether cannabis, cannabis-derived products, and synthetic cannabinoids are an effective treatment for rheumatoid arthritis.

Methods: An electronic search in Epistemonikos database was performed to identify systematic reviews and their primary studies that addressed our clinical question. The body of evidence was collected in a pivot table in Epistemonikos. Information and data from the primary studies were extracted from the identified reviews. Finally, extracted data were reanalyzed, and a summary of findings table was generated using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. It is elaborated with pre-established methods, following a friendly format for clinical professionals.

Results: Twenty-six systematic reviews were identified which included in total only 1 randomized trial assessing our clinical question. The body of evidence is very uncertain about the effect of cannabis, cannabis-derived products, and synthetic cannabinoids in RA is based on this single study (see Table 1, e567).

Conclusions: Cannabis, cannabis-derived products and synthetic cannabinoids may slightly reduce disease activity in patients with RA. Its use may result in little to no difference in pain reduction and may slightly increase nervous system adverse events. The evidence is very uncertain about the effect of cannabis, cannabis-derived products, and synthetic cannabinoids on serious adverse events risk.

Key Words: cannabinoids, cannabis, cannabis-derived products, Epistemonikos, GRADE, marijuana, medical cannabis, meta-analysis, rheumatoid arthritis, synthetic cannabinoids, systematic review

(J Clin Rheumatol 2022;28: e563–e567)

D espite great advances in rheumatoid arthritis (RA) treatment, symptoms and disease burden still cause disability, poor quality of life, and significant excess mortality, which sometimes lead patients to seek therapeutic alternatives.1–4 Although the mechanism of action of cannabis, cannabis-derived products, and synthetic cannabinoids in rheumatic diseases remains unclear, patient's interest in their medical use is rising.5,6 This fact, along with the lack of a strong evidence support, has led physicians to face great uncertainty about the benefits and risks of their prescription.7 The aim of this structured summary is to examine the therapeutic effects of cannabis, cannabis-derived products, and synthetic cannabinoids in rheumatoid arthritis.

MATERIALS AND METHODS

This article is a structured summary denominated FRISBEE (Friendly Summary of Body of Evidence using Epistemonikos), which main objective is to synthesize the body of evidence for a specific question, with a friendly format for clinical professionals. Its major resources are based on a matrix of evidence generated by Epistemonikos database software and an analysis of the body of evidence according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. It is elaborated with pre-established methods, following rigorous methodological standards and internal peer-review process. Further details of the methods for developing this FRISBEE are described elsewhere.8–10

Epistemonikos, the largest database of systematic reviews in health, was used as the primary source of information.11 Epistemonikos database is maintained by systematically screening multiple information sources, including MEDLINE, EMBASE, and Cochrane, among others, to identify systematic reviews and their included primary studies.12

A highly sensitive electronic search was conducted in Epistemonikos database in order to obtain systematic reviews assessing our clinical question. Using automated and collaborative means, all the relevant evidence for the question of interest was collected and displayed as a matrix of evidence. An evidence matrix is a table that pools the cluster of systematic reviews sharing at least 1 included study and all studies included in those reviews. Subsequently, information and data from the primary studies were extracted from the identified reviews using standardized forms. With this information, a structured summary was generated following a pre-established format, including key messages, a summary of the body of evidence (presented as an evidence matrix in Epistemonikos), a table with the characteristics of primary studies addressing the question of interest, meta-analysis of the whole studies when possible, a summary of findings (SoF) table using GRADE methodology, and a discussion about other considerations relevant for decision-making.

RESULTS

Twenty-six systematic reviews were included.14–39 Only 1 primary study,13 a randomized controlled trial included in all 26 reviews, answered the question of interest. Therefore, the information on the effects of cannabis, cannabis-derived products, and synthetic cannabinoids in RA is based on this single study (see Table 1,
which illustrates the characteristics of the body of evidence assessing cannabis, cannabis-derived products, and synthetic cannabinoids therapeutic role in rheumatoid arthritis.13

The article included 58 patients and assessed pain on movement, pain at rest, total pain intensity, morning stiffness, sleep quality, disease activity, and adverse effects.13 None of the identified systematic reviews reported physical disability or quality of life.14

The interactive version of the evidence matrix is available at the Epistemonikos web site https://www.epistemonikos.org/ under the title “Cannabis, Cannabis-Derived Products, and Synthetic Cannabinoids for Rheumatoid Arthritis.”43,44 The upper portion of the matrix will display a warning of “new evidence” if new systematic reviews are published after this structured summary.

### Summary of Findings

The SoF is as follows:

- Cannabis, cannabis-derived products, and synthetic cannabinoids may slightly reduce disease activity.
- The evidence suggests that cannabis, cannabis-derived products, and synthetic cannabinoids result in little to no difference in pain reduction.
- No studies were found that examined physical disability.
- No studies were found that assessed quality of life.
- The evidence is very uncertain about the effect of cannabis, cannabis-derived products, and synthetic cannabinoids on serious adverse events risk.

- Cannabis, cannabis-derived products, and synthetic cannabinoids may result in a slight increase in the risk of nervous system adverse events.

Key information concerning the magnitudes of relative and absolute effects of the interventions examined, the amount of available evidence, and the certainty (or quality) of available evidence is shown in Table 2. The interactive version of the SoF table can be reviewed online at https://isof.epistemonikos.org/45

### DISCUSSION

The summary of the body of evidence reveals that many systematic reviews have encompassed or addressed in some way our clinical question. Nevertheless, the reviews have found only 1 trial evaluating medical cannabinoids prescription in RA.13 The lack of articles on the topic contrasts with increasing interest of RA patients in medicinal cannabis and clinicians’ need of a strong evidence base to properly address patients’ questions.

The outcomes included in the SoF table are those considered critical for decision-making, according to the opinion of the authors of this summary, and in general coincide with the systematic reviews identified. However, physical disability and quality of life outcomes were not reported in these systematic reviews. The evidence suggests that cannabis, cannabis-derived products, and synthetic cannabinoids may slightly reduce disease activity. Nevertheless, given that the disease activity instrument used...
includes both tender joints and patient's global health self-report in its calculation, the decrease in 28-joint Disease Activity Score may be exclusively due to a reduction in pain. Because only 1 study evaluating nabiximols oromucosal spray was included in this summary, any extrapolation to other doses, compounds, therapeutic forms, and routes of administration might be premature. Accordingly, the results are applicable to patients with uncontrolled (active) RA and might not apply to patients with comorbidities such as psychiatric disorders, substance misuse, severe cardiovascular, renal or hepatic disorders, or a history of epilepsy, because they were excluded from the trial examined in this summary.13

It is not possible to make an adequate balance between benefits and risks because of the uncertainty about both. However, it is reasonable to estimate that the likelihood of a favorable balance is low. Furthermore, the follow-up period for the trial was relatively short, which is not informative in this chronic condition. In consideration of the previous information, the balance between benefits and risks should be individually assessed with patients. Synthetic cannabinoids are generally expensive. In many countries, the use and commercialization of these drugs are not authorized, so the cost associated with the process of legalization, production, commercialization, and inspection is probably substantive. Nabiximols, in particular, has a high cost, but is available as a prescription medicine in the United Kingdom, Switzerland, Norway, Turkey, Australia, New Zealand, Israel, Brazil, Colombia, and Chile, whereas approval by the US Food and Drug Administration is still pending.46

Existing evidence should lead most patients and physicians to exercise caution in using this intervention. However, given the connotation of natural medicines of cannabis-derived products and cannabis in particular, it is likely that some clinicians and patients would still be interested in these products. Therefore, studies are needed in this area to provide a better evidence-base for the use of cannabinoids in the treatment of RA.
patients might favor its use despite the information provided in this summary. The American College of Rheumatology, European League Against Rheumatism, and international guidelines do not mention cannabis, cannabis-derived products, and synthetic cannabinoids for the treatment of patients with RA.47–49 On the other hand, the College of Family Physicians of Canada recommends against the use of medical cannabinoids for pain due to rheumatologic conditions including RA,50,51 whereas the Canadian Rheumatology Association position statement on medical cannabis use in rheumatic disease recognizes the lack of evidence for its use in rheumatology patients, but encourages patients to discuss benefits and risks with their physician.52 The major part of the included systematic reviews was not specifically focused on patients with RA (e.g., noncancer chronic pain, rheumatic diseases), but most of those that made a declaration particularly for our population agreed that the evidence is insufficient to draw a conclusion.

The likelihood that the conclusions of this summary change with future evidence is high, given the scarcity of studies on the topic and the very low certainty of the evidence. Also, further research is needed addressing cannabis, cannabis-derived products, and synthetic cannabinoids other than nabiximols.

At least 3 ongoing studies that could provide relevant clinical information were identified; all of them were randomized clinical trials.53–55 Ongoing primary studies and high-quality systematic reviews reanalyzing existing data could provide conclusions with higher certainty.

REFERENCES

1. Cross M, Smith E, Hoy D, et al. The global burden of rheumatoid arthritis: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis. 2014;73:1316–1322.
2. Franke LC, Ament AJ, Van De Laar MA, et al. Cost-of-illness of rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol. 2009;27(4 suppl 55):S118–S123.
3. Sokka T, Kautiainen H, Pincus T, et al. Work disability remains a major issue in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA Study. Arthritis Res Ther. 2010;12:R42.
4. Scott IC, Iribrahim F, Lewis CM, et al. Impact of intensive treatment and remission on health-related quality of life in early and established rheumatoid arthritis. RMD Open. 2016;2:e000270.
5. Government of Canada. Canadian Alcohol and Drug Use Monitoring Survey. Published 2011. Available at: https://www.canada.ca/en/health-canada/services/health-concerns/drug-prevention-treatment/drug-alcohol-use-statistics/canadian-alcohol-drug-use-monitoring-survey-summary-results-2011.html#a3. Accessed December 29, 2019.
6. Wipfler K, Simon T, Katz P, et al. Cannabis use among patients in a large US rheumatic disease registry. In: 2019 ACR/ARP Annual Meeting. 2019. p. Available at: https://acrabstracts.org/abstract/cannabis-use-among-patients-in-a-large-us-rheumatic-disease-registries/. Accessed December 29, 2019.
7. Fitzcharles MA, Ste-Marie PA, Clauw DJ, et al. Rheumatologists lack confidence in their knowledge of cannabinoids pertaining to the management of rheumatic complaints. BMC Musculoskelet Disord. 2014;15:258.
8. Rada G. Quick evidence reviews using Epistemonikos: a thorough, friendly and current approach to evidence in health [in Spanish]. Medwave. 2014;14:e5997.
9. Rada G, Neumann I, Cerda J. A new way to find evidence quickly and efficiently. Medwave. 2014;14:e6044.
10. Rada G, Bachelet VC. Epistemonikos summaries in Medwave: reliable and user-friendly evidence that is here to stay. Medwave. 2015;15:e6232.
11. Rada G, Pérez D, Araya-Quintanilla F, et al. Epistemonikos: a comprehensive database of systematic reviews for health decision-making. BMC Med Res Methodol. 2020;20:286.
31. Whitling PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: a systematic review and meta-analysis. *JAMA*. 2015;313:2456–2473.

32. Whitling PF, Wolff RF, Westwood M, et al. *Systematic Review of Cannabis for Medical Use*. York (Riccall Road E screk York): Kleijnen Systematic Reviews Ltd; 2014.

33. Butler M, Erin Krebs M, Ben Sunderlin M, et al. *Medical Cannabis for Non-Cancer Pain: a Systematic Review*. Minnesota (Minneapolis, Minnesota): Minnesota Evidence-based Practice Center; 2017.

34. Cooper ZD, Abrams DI. Considering abuse liability and neurocognitive effects of cannabis and cannabis-derived products when assessing analgesic efficacy: a comprehensive review of randomized-controlled studies. *Am J Drug Alcohol Abuse*. 2019;45:580–595.

35. Fitzcharles MA, Ste-Marie PA, Häuser W, et al. Efficacy, tolerability, and safety of cannabinoid treatments in the rheumatic diseases: a systematic review of randomized controlled trials. *Arthritis Care Res*. 2016;68:681–688.

36. Fitzcharles MA, Baerveldt C, Ablin J, et al. Efficacy, tolerability and safety of cannabinoids in chronic pain associated with rheumatic diseases (fibromyalgia syndrome, back pain, osteoarthritis, rheumatoid arthritis): a systematic review of randomized controlled trials. *Schmerz*. 2016;30:47–61.

37. Haleen R, Wright R. A scoping review on clinical trials of pain reduction with cannabis administration in adults. *J Clin Med Res*. 2020;12:344–351.

38. Hassan S. Cannabinoids for the treatment of chronic pain: a critical review of randomized controlled trials. *J Pain Manag Med*. 2018;04:1–7.

39. Hazekamp A, Grotenhermen F. Review on clinical studies with cannabis and cannabinoids 2005–2009. *Cannabinoids*. 2010;5(special issue):1–21.

40. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum*. 1988;31:315–324.

41. Schulze C, Duran J, Rada G, et al. Cannabis, cannabis-derived products and synthetic cannabinoids for rheumatoid arthritis: matrix of evidence. Available at: https://www.epistemonikos.org/matrixes/5f2e3d27aacc848bf25cc81. Accessed February 5, 2021.

42. Wells G, Becker JC, Teng J, et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. *Ann Rheum Dis*. 2009;68:954–960.

43. Van Gestel A, Prevo M, Van ’T Hof M, et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. *Arthritis Rheum*. 1996;39:34–40.

44. Melzack R. The short-form McGill Pain Questionnaire. *Pain*. 1987;30:191–197.

45. Schulze C, Bravo R, Verdugo F, et al. Therapeutic use of cannabis, cannabis-derived products and synthetic cannabinoids for rheumatoid arthritis: interactive summary of findings. Published 2020. Available at: https://isof.epistemonikos.org/#!/finding/5fd3d0ce3089d04c181b23. Accessed February 5, 2021.

46. Information on obtaining Sativex® | GW Pharmaceuticals plc. Available at: https://www.gwpharm.com/healthcare-professionals/sativex/ prescribing-information. Accessed December 25, 2020.

47. Baker JF, Barbour KE, Barton J, et al. American College Of Rheumatology Updated Guideline for the Management of Rheumatoid Arthritis Literature Review Team; 2018.

48. Smolen JS, Landèved RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. *Ann Rheum Dis*. 2020;79:685–699.

49. Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. *Ann Rheum Dis*. 2016;75:3–15.

50. Allan GM, Ramji J, Perry D, et al. Simplified guideline for prescribing medical cannabinoids in primary care. *Can Fam Physician*. 2018;64:111–120.

51. Fitzcharles MA, Niaki OZ, Hauser W, et al. Position statement: a pragmatic approach for medical cannabis and patients with rheumatic diseases. *J Rheumatol*. 2019;46:532–538.

52. Canadian Rheumatology Association. Canadian Rheumatology Association (CRA) position statement on medical cannabis use in rheumatic disease. Published 2019. Available at: https://rheum.ca/canadian-rheumatology-association-cra-position-statement-on-medical-cannabis-use-in-rheumatic-disease-faq/. Accessed November 18, 2020.

53. King Christian 10th Hospital for Rheumatic Diseases. 2017-004226-15: CAN-ART. The efficacy and safety of using cannabis derivatives cannabidiol (CBD) and tetrahydrocannabinol (THC) for the treatment of pain in patients with inflammatory arthritis (RA, AS): a randomized, double blinded, placebo controlled trial. Published 2017. Available at: https://www.clinicaltrialregister.eu/ctr-search/trial/2017-004226-15/DK. Accessed November 23, 2020.

54. Aston E. NCT04269993: impact of acute cannabis administration on pain symptomology and inflammatory markers among patients with rheumatoid or psoriatic arthritis. Available at: https://clinicaltrials.gov/ct2/show/ NCT04269993. Accessed November 23, 2020.

55. Zaskow C. ISRCTN29199098: efficacy of a topical cannabinoid preparation in decreasing symptoms of rheumatoid arthritis. Published 2014. Available at: http://www.isrctn.com/ISRCTN29199098. Accessed November 23, 2020.

© 2021 The Author(s). Published by Wolters Kluwer Health, Inc.